Gut Guardians: How Specialized Immune Cells Fight Colorectal Cancer
"New research unveils how CD19loCD27hi plasmablasts use interleukin-10 to tame harmful inflammation and improve survival rates in colorectal cancer patients."
Colorectal cancer (CRC) is a major health challenge, and our immune system plays a complex role in its development. While much attention has been given to T cells, regulatory B cells (Bregs) are emerging as key players in controlling inflammation and influencing the course of the disease. Bregs are known to communicate with other immune cells and release substances that can dampen down excessive immune responses.
Previous studies have shown that the presence of certain immune cells, specifically CD20+ and CD138+ cells, in and around colorectal tumors is associated with better survival rates. Expanding on this, researchers have discovered that tumors in CRC patients are often rich in CD19loCD27hi plasmablasts, a unique type of Breg that produces interleukin-10 (IL-10). IL-10 is a powerful anti-inflammatory molecule, suggesting that these plasmablasts might be working to suppress harmful immune reactions within the tumor.
To understand the role of CD19loCD27hi plasmablasts in CRC, a new study has investigated how these cells function and what effects they have on other immune cells. The research focuses on how these plasmablasts, through the production of IL-10, can suppress inflammation and potentially improve outcomes in CRC patients.
Immune Context Shapes CRC
Colorectal cancer is described as the second most common cause of cancer death worldwide. Its immune landscape includes diverse immune cells that influence tumor development, progression, metastasis, and responses to therapy. B cells are associated with improved prognosis, while a publicly available dataset integrating RNA, whole-exome, T-cell receptor, and 16S rRNA sequencing has enabled discovery of a prognostic score for colon cancer.
Measuring Immune Infiltration
The Immunoscore quantifies immune contexture by measuring CD3+ and CD8+ T-cell densities in the tumor center and invasive margin. The cited source reports that it provides stronger prognostic performance than TNM staging or mismatch-repair status alone and that international cohorts have validated its ability to predict benefit from adjuvant chemotherapy in stage-specific disease. Other accepted approaches include tissue microarrays and immunohistochemistry to evaluate infiltrating populations such as CD3, CD4, CD8, CD20, CD23, CD45, and CD56 cells. Despite progress in immune-checkpoint therapies, reviews continue to identify important obstacles and limitations.
From Cancer History to the Tumor Microenvironment
Cancer research has produced landmark discoveries over the past 250 years, as documented by the National Cancer Institute's historical timeline. More recent colorectal cancer research has expanded from tumor-centered explanations to the study of tumor-infiltrating immune cells and their pathophysiological and prognostic roles. Current reviews describe the tumor microenvironment as an interacting system containing stromal and endothelial cells, extracellular matrix, gut microbiota, and diverse immune cells that can influence tumor initiation.
Unlocking the Secrets of CD19loCD27hi Plasmablasts: A Step-by-Step Investigation
To better understand these unique plasmablasts, the researchers first needed a way to study them in the lab. They developed a method to stimulate ordinary B cells from patient blood samples to transform them into cells resembling the tumor-infiltrating plasmablasts. This involved co-culturing the B cells with Caco-2 cells (a common colorectal cancer cell line) and heat-killed bacteria.
- Suppressing Harmful Inflammation: The scientists discovered that CD19loCD27hi plasmablasts could significantly reduce the production of IL-17A, a molecule that promotes inflammation, by other immune cells.
- Targeting a Key Inflammatory Driver: The plasmablasts also suppressed RORyt, a protein that drives the development of Th17 cells, which are major contributors to inflammation in CRC.
- IL-10: The Key Mediator: Through experiments that blocked IL-10, the researchers confirmed that IL-10 production was the primary way these plasmablasts suppressed inflammation.
Mapping B-Cell Diversity
A recent study developed a seven-plex immunohistochemistry assay combined with machine-learning image analysis to distinguish B-cell and plasma-cell populations in the colorectal cancer microenvironment. The method was applied to a cohort of 912 colorectal tumors. This approach is designed to examine the prognostic role of multiple B-cell and plasma-cell subsets rather than treating all B cells as a single population.
Limits of Immune Biomarkers
Studies of immune biomarkers face methodological limits that can affect interpretation. One study of CD20+ B lymphocytes used tissue microarrays because its method was not optimal for large cohorts using whole tissue sections; this prevented assessment of the often heterogeneous distribution of immune cells and avoidance of areas such as necrosis. A separate study of baseline serum IL-17A in metastatic colorectal cancer patients receiving a bevacizumab-based regimen had no control arm without bevacizumab, so its findings were prognostic rather than evidence of predictive treatment value. The authors reported that additional studies are needed for validation.
Different Cells, Different Signals
CD8+ cells were linked to improved survival in stages I-III colon cancer, whereas CD4+ cells had the strongest association with overall survival in metastatic colorectal cancer. Tumor samples also contained a higher percentage of CD19+ cells than patients' peripheral blood mononuclear cells, 8.9% versus 5.1% of CD45+ lymphocytic cells. In another analysis, patients with high infiltration by CD20+CD73+ B cells, using a median threshold of 51,589 cells per gram of tissue, had significantly more favorable overall survival than patients with low infiltration.
The Promise of Immune-Based Therapies for Colorectal Cancer
This research highlights the potential of harnessing the immune system to fight colorectal cancer. By understanding how specific immune cells like CD19loCD27hi plasmablasts can suppress inflammation and improve outcomes, researchers can develop new therapies that boost these beneficial immune responses. Future studies will focus on how to enhance the activity of these plasmablasts or develop drugs that mimic their anti-inflammatory effects, offering new hope for more effective CRC treatments.
Immune Cells Can Have Dual Effects
Human colorectal cancer research shows that immune cells can produce both harmful and beneficial effects. CRC-derived Th17 cells can release IL-17, prompting tumor and tumor-associated stromal cells to produce protumorigenic factors. At the same time, these cells can recruit beneficial neutrophils through IL-8 and drive highly cytotoxic CCR5+CCR6+CD8+ T cells into tumor tissue through CCL5 and CCL20. Reviews of innate immune cells and immune-cell-based therapies emphasize that these complex roles remain important for future research and clinical trials.